Equity research analysts tracking Smith & Nephew (NYSE: SNN) maintain 12-month consensus price forecasts that project steady upward movement, with average targets pointing toward moderate upside potential. Financial models evaluate the company's valuation based on anticipated revenue growth acceleration in its sports medicine and restructured orthopedics divisions, alongside ongoing operational efficiency savings.